Monique Hinchcliff1, Steven O'Reilly2. 1. Section of Rheumatology and allergy, Yale School of medicine, Yale University, New Haven, CT, USA. 2. Department of Biosciences, Durham University, Stockton Road, Durham, UK. steven.o'reilly@durham.ac.uk.
Abstract
PURPOSE OF REVIEW: Systemic sclerosis (SSc) is an autoimmune connective tissue disease in which there is an activation of fibroblast to a myofibroblast that secretes huge amounts of extracellular matrix. Currently, no treatment exists that modifies the fibrosis elements and new therapeutic targets are badly needed. This review examines the current state of treatments and emerging therapeutics. RECENT FINDINGS: Nintedanib was found to significantly reduce the rate of decline in SSc associated FVC, although it has no benefit on skin fibrosis. New cannabinoid receptor2 agonist has shown superb effects in phase II and results in phase III are anticipated. Other targets are currently being tested in clinical trials and new targets that are yet to be tested are increasing in the SSc literature. Nintedanib is now licenced for SSc interstitial lung disease but this does not modify the skin fibrosis. Current ongoing trials will determine the role of various targets. New targets are emerging as we gain a deeper understanding of disease pathogenesis.
PURPOSE OF REVIEW: Systemic sclerosis (SSc) is an autoimmune connective tissue disease in which there is an activation of fibroblast to a myofibroblast that secretes huge amounts of extracellular matrix. Currently, no treatment exists that modifies the fibrosis elements and new therapeutic targets are badly needed. This review examines the current state of treatments and emerging therapeutics. RECENT FINDINGS:Nintedanib was found to significantly reduce the rate of decline in SSc associated FVC, although it has no benefit on skin fibrosis. New cannabinoid receptor2 agonist has shown superb effects in phase II and results in phase III are anticipated. Other targets are currently being tested in clinical trials and new targets that are yet to be tested are increasing in the SSc literature. Nintedanib is now licenced for SSc interstitial lung disease but this does not modify the skin fibrosis. Current ongoing trials will determine the role of various targets. New targets are emerging as we gain a deeper understanding of disease pathogenesis.
Authors: Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni Journal: Pharmaceuticals (Basel) Date: 2021-04-23
Authors: Ana Paula Pereira Velosa; Lais Brito; Zelita Aparecida de Jesus Queiroz; Solange Carrasco; Jurandir Tomaz de Miranda; Cecília Farhat; Cláudia Goldenstein-Schainberg; Edwin Roger Parra; Danieli Castro Oliveira de Andrade; Pedro Leme Silva; Vera Luiza Capelozzi; Walcy Rosolia Teodoro Journal: Front Immunol Date: 2021-02-12 Impact factor: 7.561
Authors: Naoko Takamura; Ludivine Renaud; Willian Abraham da Silveira; Carol Feghali-Bostwick Journal: Front Immunol Date: 2021-11-29 Impact factor: 7.561
Authors: Laura Duffy; John Henderson; Max Brown; Stefan Pryzborski; Nicola Fullard; Lena Summa; Jorg H W Distler; Richard Stratton; Steven O'Reilly Journal: Front Cell Dev Biol Date: 2021-06-04